CBD may help early psychosis along with usual treatment
Treatments studied
Part of Mental health clinical trials.
This Phase 3 trial tests whether taking cannabidiol (CBD) can reduce symptoms when added to standard care for early psychosis (like first-episode psychosis or attenuated psychosis). It may help some people have fewer troubling thoughts or perceptions over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your psychosis symptoms started within the last 2 years (first episode) or you have attenuated psychosis syndrome (APS)
- You have been stable on the same treatment plan for at least 8 weeks (no major change in medications/doses recently)
- Your current symptoms are not too severe right now (only up to mild-to-moderate “positive” symptoms)
- Your depression symptoms are low based on a schizophrenia depression rating scale
- You must not have certain medical/neurologic conditions, major head injury, or high suicide risk
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at people who have had psychosis for less than 4 years to understand how their symptoms change over time and how they respond to treatment. By using brain scans and other tests, researchers hope to find better ways to personalize care for early psychosis.
This study tests if adding a CBD medication to your current antipsychotic can improve symptoms in people with schizophrenia or related disorders who started treatment recently but aren't fully better yet.
This trial tests whether adding a cannabis-based medicine called cannabidiol (CBD) to clozapine helps people with early psychosis who still have symptoms. It may improve your symptoms and overall well-being.
This study tests whether a medication called cannabidiol (a non-intoxicating compound from cannabis) can help reduce symptoms and prevent progression in young people at clinical high risk for psychosis. Participants will receive either the study drug or a placebo (a pill with no active ingredient) and will be followed to see how they respond.
This Phase 2 study tests whether cannabidiol (CBD) can reduce anxiety and depressive symptoms in people with bipolar disorder. It may help if your mood symptoms are persistent and you’re already on stable bipolar medications.
This trial tests whether cannabidiol (CBD) can reduce symptoms of bipolar depression. You may be eligible if you have bipolar I or II and a current depressive episode while staying on approved mood-stabilizing or antipsychotic medication.
Hear when a new Early Psychosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.